Literature DB >> 24211297

Development and comparison of a quantitative TaqMan-MGB real-time PCR assay to three other methods of quantifying vaccinia virions.

Jonathon L Baker1, Brian M Ward2.   

Abstract

Plaque assays are a widely used method to quantify stocks of viruses. Although this method is well established for titrating viral stocks, it is time consuming and can take several days to complete. In this study, the creation and validation of a quantitative real-time PCR (qPCR) assay for enumerating virions of vaccinia virus is reported. PCR primers and a minor groove-binding probe were designed to hybridize to the DNA polymerase gene (E9L) from a number of different orthopoxviruses. The number of viral genomes determined using qPCR was approximately similar to results obtained using OD260 measurements and a direct count of fluorescent virions by microscopy indicating that all three methods are comparable in their ability to quantify virions from a purified stock. In addition, this report describes methodologies to harvest and quantify, using the qPCR assay, three of the four types of vaccinia virions produced during morphogenesis: intracellular mature virions, cell-associated enveloped virions, and extracellular enveloped virions. Using these procedures a particle to plaque forming unit of 61:1, 14:1 and 6:1 was calculated for IMV, CEV and EEV, respectively. These results show that qPCR can be used as a fast and accurate assay to quantify stocks of vaccinia virus over several orders of magnitude from both purified and unpurified stocks and should be applicable to other members of the orthopoxvirus genera.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Orthopoxvirus; Particle to PFU ratio; Vaccinia virus; qPCR

Mesh:

Substances:

Year:  2013        PMID: 24211297      PMCID: PMC3889198          DOI: 10.1016/j.jviromet.2013.10.026

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  42 in total

1.  Entry of the two infectious forms of vaccinia virus at the plasma membane is signaling-dependent for the IMV but not the EEV.

Authors:  J K Locker; A Kuehn; S Schleich; G Rutter; H Hohenberg; R Wepf; G Griffiths
Journal:  Mol Biol Cell       Date:  2000-07       Impact factor: 4.138

2.  Simultaneous high-resolution analysis of vaccinia virus and host cell transcriptomes by deep RNA sequencing.

Authors:  Zhilong Yang; Daniel P Bruno; Craig A Martens; Stephen F Porcella; Bernard Moss
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-07       Impact factor: 11.205

3.  The vaccinia virus A27L protein is needed for the microtubule-dependent transport of intracellular mature virus particles.

Authors:  C M Sanderson; M Hollinshead; G L Smith
Journal:  J Gen Virol       Date:  2000-01       Impact factor: 3.891

Review 4.  Targeted and armed oncolytic poxviruses for cancer: the lead example of JX-594.

Authors:  Caroline J Breitbach; Steve H Thorne; John C Bell; David H Kirn
Journal:  Curr Pharm Biotechnol       Date:  2012-07       Impact factor: 2.837

Review 5.  Poxviral vectors for cancer immunotherapy.

Authors:  Joseph W Kim; James L Gulley
Journal:  Expert Opin Biol Ther       Date:  2012-04       Impact factor: 4.388

6.  Real-time PCR to identify variola virus or other human pathogenic orthopox viruses.

Authors:  Natale Scaramozzino; Audrey Ferrier-Rembert; Anne-Laure Favier; Corinne Rothlisberger; Stéphane Richard; Jean-Marc Crance; Hermann Meyer; Daniel Garin
Journal:  Clin Chem       Date:  2007-03-01       Impact factor: 8.327

Review 7.  Modified Vaccinia virus Ankara: innate immune activation and induction of cellular signalling.

Authors:  Philip J R Price; Lino E Torres-Domínguez; Christine Brandmüller; Gerd Sutter; Michael H Lehmann
Journal:  Vaccine       Date:  2013-03-21       Impact factor: 3.641

8.  Diagnosis and assessment of monkeypox virus (MPXV) infection by quantitative PCR assay: differentiation of Congo Basin and West African MPXV strains.

Authors:  Masayuki Saijo; Yasushi Ami; Yuriko Suzaki; Noriyo Nagata; Naoko Iwata; Hideki Hasegawa; Momoko Ogata; Shuetsu Fukushi; Tetsuya Mizutani; Itoe Iizuka; Koji Sakai; Tetsutaro Sata; Takeshi Kurata; Ichiro Kurane; Shigeru Morikawa
Journal:  Jpn J Infect Dis       Date:  2008-03       Impact factor: 1.362

Review 9.  Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer.

Authors:  David H Kirn; Steve H Thorne
Journal:  Nat Rev Cancer       Date:  2009-01       Impact factor: 60.716

10.  Repulsion of superinfecting virions: a mechanism for rapid virus spread.

Authors:  Virginie Doceul; Michael Hollinshead; Lonneke van der Linden; Geoffrey L Smith
Journal:  Science       Date:  2010-01-21       Impact factor: 47.728

View more
  12 in total

1.  Droplet digital PCR for rapid enumeration of viral genomes and particles from cells and animals infected with orthopoxviruses.

Authors:  Jeffrey L Americo; Patricia L Earl; Bernard Moss
Journal:  Virology       Date:  2017-08-10       Impact factor: 3.616

2.  The Ectodomain of the Vaccinia Virus Glycoprotein A34 Is Required for Cell Binding by Extracellular Virions and Contains a Large Region Capable of Interaction with Glycoprotein B5.

Authors:  Stephanie R Monticelli; Amalia K Earley; Jessica Tate; Brian M Ward
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

3.  Vaccinia Virus Phospholipase Protein F13 Promotes Rapid Entry of Extracellular Virions into Cells.

Authors:  Peter Bryk; Matthew G Brewer; Brian M Ward
Journal:  J Virol       Date:  2018-05-14       Impact factor: 5.103

4.  The Molluscum Contagiosum Gene MC021L Partially Compensates for the Loss of Its Vaccinia Virus Homolog, F13L.

Authors:  Stephanie R Monticelli; Peter Bryk; Brian M Ward
Journal:  J Virol       Date:  2020-09-29       Impact factor: 5.103

5.  Collateral Lethal Effects of Complementary Oncolytic Viruses.

Authors:  Justin W Maroun; Velia Penza; Taylor M Weiskittel; Autumn J Schulze; Stephen J Russell
Journal:  Mol Ther Oncolytics       Date:  2020-06-24       Impact factor: 7.200

6.  Enhanced Efficacy of Vaccination With Vaccinia Virus in Old vs. Young Mice.

Authors:  Evgeniya V Shmeleva; Geoffrey L Smith; Brian J Ferguson
Journal:  Front Immunol       Date:  2019-07-31       Impact factor: 7.561

7.  Safety, biodistribution and viral shedding of oncolytic vaccinia virus TG6002 administered intravenously in healthy beagle dogs.

Authors:  Jérémy Béguin; Murielle Gantzer; Isabelle Farine; Johann Foloppe; Bernard Klonjkowski; Christelle Maurey; Éric Quéméneur; Philippe Erbs
Journal:  Sci Rep       Date:  2021-01-26       Impact factor: 4.379

8.  The basic reproductive number and particle-to-plaque ratio: comparison of these two parameters of viral infectivity.

Authors:  Winston McCormick; Leonard A Mermel
Journal:  Virol J       Date:  2021-04-30       Impact factor: 4.099

9.  An increase in glycoprotein concentration on extracellular virions dramatically alters vaccinia virus infectivity and pathogenesis without impacting immunogenicity.

Authors:  Stephanie R Monticelli; Peter Bryk; Matthew G Brewer; Hector C Aguilar; Christopher C Norbury; Brian M Ward
Journal:  PLoS Pathog       Date:  2021-12-28       Impact factor: 6.823

10.  CCL5-armed oncolytic virus augments CCR5-engineered NK cell infiltration and antitumor efficiency.

Authors:  Feng Li; Yuqiao Sheng; Weizhou Hou; Padma Sampath; Daniel Byrd; Stephen Thorne; Yi Zhang
Journal:  J Immunother Cancer       Date:  2020-02       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.